Abstract:Objective: The prevalence of non-alcoholic fatty liver disease (NAFLD) has markedly increased. Insulin resistance has been implicated in the pathogenesis of NAFLD. This study was aimed at observing the relationship between insulin resistance and NAFLD, and evaluating the role of pioglitazone (PGZ) acting as insulin-sensitizing agents in the prevention and treatment of rat fatty liver induced by high fat feeding. Methods: The rats were separated randomly into 6 groups: model group I were fed high fat diet for 8 weeks, PGZ prevention group were given PGZ 4 mg/(kg·d) simultaneously, while control group I were fed normal food for 8 weeks; model group II were fed high fat diet for 16 weeks, PGZ treatment group were given PGZ 4 mg/(kg·d) orally simultaneous with high fat diet for 8 weeks after high fat feeding for 8 weeks, control group II were fed normal food for 16 weeks. The rats were sacrificed after 8 weeks and 16 weeks respectively. Liver weight, body weight, serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), tumor necrosis factor alpha (TNF-α), fasting blood glucose (FBG), fasting plasma insulin (FINS), HOMA (homeostasis model assessment) insulin resistance index (HOMA-IR), and the liver histology of rats of all groups were assayed. Results: After 8 weeks, the liver in model group I showed typical steatosis, accompanied with mild to moderate lobular inflammatory cell infiltration, liver indexes and serum levels of ALT, AST, ALP, TNF-α were significantly increased ( P <0.05) compared with control group I. Whereas, the degree of hepatic injury was attenuated in PGZ prevention group, liver indexes and serum levels of ALT, ALP were significantly decreased ( P <0.05) compared with model group I. After 16 weeks, notable steatosis, and lobular inflammation were observed in model group II rat liver, while the degree of hepatic injury was attenuated in the PGZ treatment group. Liver index, serum levels of ALT, AST, ALP, FINS and HOMA-IR were significantly increased ( P <0.05) in model group II compared with control group II. Whereas, in PGZ treatment group, serum levels of AST and FINS showed decreasing tendency, liver indexes, serum levels of ALT, ALP, TNF-α and HOMA-IR were significantly decreased compared with model group II. Conclusion: Insulin resistance plays a role in the pathogenesis of NAFLD in rats. Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats.

Therapeutic Effect of Teduglutide on Non-Alcoholic Fatty Liver Disease in Rats

Effects of Glucagon?Like Peptide?1 Analog on CDAA Diet?Induced Models of Nonalcoholic Fatty Liver Fibrosis in Rats

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling

Research on the Protection Effect of Pioglitazone for Non-Alcoholic Fatty Liver Disease (NAFLD) in Rats

The Preventive Effect of Liraglutide on the Lipotoxic Liver Injury Via Increasing Autophagy

Efficacy of liraglutide in the treatment of nonalcoholic fatty liver disease:a Meta analysis

Effect of GLP-1 on insulin resistance and PKCεin rats with nonalcoholic fatty liver disease induced by high fat diet

Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice

Experimental Study on the Glucagon-Likepeptide 1 Receptor Agonist Modulation of Insulin Resistance and Hepatic Oxidative Stress in Rats with Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Effects of Liraglutide on the lipid profile in high-fat diet rats

1751-P: Induction of Sirt1-AMPK Pathway by GLP-1RA Liraglutide Reduces Hepatic Lipid Accumulation and Insulin Resistance

Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease

Liraglutide Ameliorates Non-Alcoholic Fatty Liver Disease by Enhancing Mitochondrial Architecture and Promoting Autophagy Through the SIRT1/SIRT3-FOXO3a Pathway.

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway

Effects of Liraglutide on Endoplasmic Reticulum Stress in Mice with T2DM and Fatty Livers

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway

Liraglutide on Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 16 RCTs

Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells